STOP-HAE
51 evidence topics · 15 sources
Objective
Registry brief summary
Primary and secondary objectives
Location and study date
Trial initiation, planned sites, and topline timing
Sites and countries reported at EAACI 2026
UK research ethics committee opinion
| Field | Reported value |
|---|---|
| REC reference | “25/NE/0161” |
| Date of REC opinion | “16 Oct 2025” |
| REC opinion | “Further Information Favourable Opinion” |
Topline data timing at the Q3 2026 update
Study design
Registry design details
| Field | Reported value |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Model description | “Randomized, double-blind, placebo-controlled study” |
| Masking | “Quadruple” |
| Masking description | “Double blinded” |
Washout, screening, and randomization
Post-dose visits and study duration
Participant timeline on the trial website
Transition to the long-term extension
Regulatory input on the phase 3 design
Eligibility criteria
Registry key inclusion criteria
Registry washout periods for long-term prophylaxis
EU record: laboratory criteria for the HAE diagnosis
EU record: suitability for on-demand treatment alone
EU record: renal function, ACE inhibitors, estrogens, and prior RNA therapy
Trial website criteria: prophylaxis discontinuation, medical history, and eDiary
Treatment
Registry interventions
| Intervention | Reported description |
|---|---|
| ADX-324 | “siRNA duplex oligonucleotide” |
| Placebo | “saline” |
Randomized treatment groups and injection volumes
| Treatment group | Reported value |
|---|---|
| Onvuzosiran every 6 months | “ADX-324 300 mg Q6M (1.5ml)” |
| Onvuzosiran every 3 months | “ADX-324 240 mg Q3M (1.2ml)” |
| Placebo, larger volume | “Placebo (1.5 ml) n=15” |
| Placebo, smaller volume | “Placebo (1.2 ml) n=15” |
Dose selection relative to the phase 2a doses
Pharmacodynamic target for the 300 mg dose
Number of active doses during the controlled period
On-demand treatment and home nursing visits
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Exclusion of attacks before Day 22
Attack recording by daily eDiary
Guideline treatment goal: absence of attacks
“We recommend that the goals of treatment are to achieve total control of the disease and to normalize patients' lives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Complete control of their disease, for HAE patients, translates to no longer having attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These treatments significantly reduce attack rates, and many patients achieve complete response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2a relationship between prekallikrein suppression and attacks
Secondary endpoints: registry definitions
Exploratory endpoint instruments
Validation of outcomes instruments: AECT scoring and cut-off
Validation of outcomes instruments: AECT development
“A 4-item AECT with recall periods of 4 weeks and 3 months was developed based on 106 potential items tested in 97 patients with mast cell mediator-induced (n = 49) or bradykinin-mediated recurrent AE (n = 48).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Its validity and reliability need to be determined in future independent studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Validation of outcomes instruments: AE-QoL minimal clinically important difference
Validation of outcomes instruments: AE-QoL content validation and psychometric evaluation
Validation of outcomes instruments: AE-QoL content validation in adults and adolescents
Validation of outcomes instruments: AE-QoL psychometric validation
Statistical analysis description
Number of participants (Planned and analyzed)
Registry planned enrollment
Planned participants per treatment group
| Treatment group | Planned participants |
|---|---|
| “ADX-324 300 mg Q6M (1.5ml)” | “n=30” |
| “ADX-324 240 mg Q3M (1.2ml)” | “n=30” |
| Placebo | “Placebo (1.2 ml) n=15 or (1.5 ml) n=15” |
Participants analyzed
No evidence found.
Description of analysis sets
Primary comparison and superiority criterion
Analysis populations
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
No results are available. The trial began in August 2025, enrollment is ongoing, and the estimated primary completion date is November 2027, with topline data expected by the end of 2027. Planned enrollment is approximately 90 participants: 30 per onvuzosiran group and 30 receiving placebo, divided into two injection volumes of 15 participants each. This sample size limits the precision of safety estimates and of any subgroup analysis. The primary endpoint compares only the 300 mg every-6-months group with placebo; the 240 mg every-3-months comparison is a secondary endpoint. The controlled period lasts 25 weeks, so participants in the every-6-months group receive one active dose and the controlled data do not cover a second 6-month dosing interval. Attacks before Day 22 are excluded from the primary analysis, so the primary endpoint does not describe protection during the first 3 weeks after the first dose. The comparator is placebo, so the trial does not provide a direct comparison with an approved long-term prophylactic agent. Eligibility is limited to adults with type I or type II HAE who have at least 1 investigator-confirmed attack in the first 4 weeks of screening or at least 2 in 8 weeks, who complete washout of long-term prophylaxis, and who are judged able to use on-demand treatment alone; HAE with normal C1 inhibitor, clinically significant renal or hepatic disease, and prior RNA- or DNA-based HAE therapy are excluded. The doses were selected from pharmacodynamic data in healthy volunteers and from the attack-free intervals of 3 participants with HAE whose phase 2a doses were lower or less frequent than the phase 3 regimens. The design is described only in the registry record, ethics summaries, and sponsor documents; no peer-reviewed protocol publication was identified.